Federal contract award
75N91021F00003
PREVENT CANCER PRECLINICAL DRUG DEVELOPMENT PROGRAM - A NOVEL MULTI-ANTIGEN VACCINE (TNBCVAX) TO PREVENT TRIPLE NEGATIVE BREAST CANCER
Award details
Obligations, current value and potential value describe different measures; they are never added together.
| Field | Reported value |
|---|---|
| Agency | Department of Health and Human Services |
| Office | NIH NCI |
| NAICS | 541714 — Research and Development in Biotechnology (except Nanobiotechnology) |
| PSC | AN12 — HEALTH R&D SERVICES; HEALTH CARE SERVICES; APPLIED RESEARCH |
| Parent award / vehicle | 75N91019D00020 |
| Set-aside | Not reported |
| Pricing type | FIRM FIXED PRICE |
| Obligations | $1.1M |
| Current contract value | $1.1M |
| Potential contract value / ceiling | $1.1M |
| Start date | Sep 16, 2021 |
| Current end date | Nov 15, 2025 |
| Potential end date | Nov 15, 2025 |
| Latest award activity | Apr 10, 2026 |
| Source loaded | Sep 26, 2026 |
Funding and modification history
Showing the latest 6 of 6 loaded transactions. Negative values are deobligations.
| Date | Modification | Obligation change | Description |
|---|---|---|---|
| Apr 10, 2026 | P00005 | $-6.0K | PREVENT CANCER PRECLINICAL DRUG DEVELOPMENT PROGRAM, TASK ORDER TITLE: A NOVEL MULTI-ANTIGEN VACCINE (TNBCVAX) TO PREVENT TRIPLE NEGATIVE BREAST CANCER |
| Mar 5, 2025 | P00004 | $0 | PREVENT CANCER PRECLINICAL DRUG DEVELOPMENT PROGRAM, TASK ORDER TITLE: A NOVEL MULTI-ANTIGEN VACCINE (TNBCVAX) TO PREVENT TRIPLE NEGATIVE BREAST CANCER |
| Jan 6, 2025 | P00003 | $0 | PREVENT CANCER PRECLINICAL DRUG DEVELOPMENT PROGRAM, TASK ORDER TITLE: A NOVEL MULTI-ANTIGEN VACCINE (TNBCVAX) TO PREVENT TRIPLE NEGATIVE BREAST CANCER |
| Jun 27, 2024 | P00002 | $0 | PREVENT CANCER PRECLINICAL DRUG DEVELOPMENT PROGRAM, TASK ORDER TITLE: A NOVEL MULTI-ANTIGEN VACCINE (TNBCVAX) TO PREVENT TRIPLE NEGATIVE BREAST CANCER |
| Aug 4, 2022 | P00001 | $631.0K | PREVENT CANCER PRECLINICAL DRUG DEVELOPMENT PROGRAM, TASK ORDER TITLE: A NOVEL MULTI-ANTIGEN VACCINE (TNBCVAX) TO PREVENT TRIPLE NEGATIVE BREAST CANCER |
| Sep 13, 2021 | 0 | $482.5K | PREVENT CANCER PRECLINICAL DRUG DEVELOPMENT PROGRAM - A NOVEL MULTI-ANTIGEN VACCINE (TNBCVAX) TO PREVENT TRIPLE NEGATIVE BREAST CANCER |
Research next steps
- Confirm the ordering vehicle and your eligibility or a qualified teaming route.
- Review the award scope and buyer evidence before making a bid/no-bid decision.